1. Introduction {#sec1}
===============

Human milk is considered as the "gold standard" of infant nutrition during the first few months of human life. The composition of human milk is unique and it is adapted for the infant\'s immature digestive and immune systems. Human milk protects infants from infection and inflammation, promotes development of immunity, and facilitates organ maturation \[[@B1]\]. Human milk oligosaccharides (HMOs) are a part of functional ingredients of the breast milk. HMOs are complex glycans that are found in high concentrations and with unique structural diversity. HMOs are the third most abundant components of milk after lactose and lipids \[[@B2]\].

2. Structure of HMOs {#sec2}
====================

Although HMOs are of various types and carry out diverse functions, they have a basic structural blueprint ([Figure 1](#fig1){ref-type="fig"}). Five monosaccharides represent the building blocks of HMOs, namely, glucose, galactose,*N*-acetylglucosamine, fucose, and*N*-acetylneuraminic acid \[[@B3]\]. A proportion of 35-50% of fucosylated, 12-14% of sialylated, and 42-55% of nonfucosylated neutral HMOs has been reported in term breast milk \[[@B4]\]. In colostrum, transitional and mature milk HMO concentrations may exceed up to 20 g/L and drop to 5-12 g/L \[[@B5]\].

Although the synthetic oligosaccharides such as galactooligosaccharides (GOS) and fructooligosaccharides (FOS) and pectin-derived acidic oligosaccharide (pAOS) have been introduced into the infant formula, they are structurally different from the HMOs. Fructose or its polymers as well as galacturonic acid and its homo- or heteropolymers are not found in human milk. Fucosylated and sialylated oligosaccharides are important HMOs that are yet to be synthesized \[[@B2]\]. However, the European Food Safety Authority (EFSA) and the U.S. Food and Drug Administration (FDA) have independently confirmed the safety of 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT) for administration to babies through infant formulas.

2.1. Types of HMOs {#sec2.1}
------------------

HMOs are classified into three types \[[@B6]\]:Neutral or fucosylated HMOs: these HMOs contain fucose at the terminal position. Examples: 2\'-fucosyllactose (2\'-FL) and lactodifucopentose.Neutral N-containing or nonfucosylated HMOs: these HMOs contain N-acetylglucosamine at the terminal end. Example: lacto-N-tetraose.Acidic or sialylated HMOs: these HMOs contain sialic acid at the terminal end. Example: 2\'-sialyllactose.

3. Variation in HMOs {#sec3}
====================

The total HMO concentration decreases within the first 3 months, but the level of some HMOs may increase \[[@B5]\]. More than a hundred different HMOs have been identified so far, but not every woman synthesizes the same set of oligosaccharides due to the role of various factors \[[@B2]\]. It is of clinical interest to understand how the multifactorial web of causation may influence the quantity and quality of HMOs in the breast milk.

3.1. Secretor Status and Lewis Blood Group {#sec3.1}
------------------------------------------

Significant biological variation is evident in specific HMO structures such as 2′-FL and lacto-N-fucopentaose I and II (LNFP I and LNFP II) in mature term breast milk. The variation in *α*1-2-fucosylated HMOs is dependent on the mother\'s genes that encode for fucosyltransferase (FUT) enzymes, which in turn are determined by the secretor (Se) status and Lewis (Le) blood group \[[@B7]\]. Abundant levels of 2\'FL, LNFP I, and other *α*1-2-fucosylated HMOs are present in the milk of secretor mothers. However, fucosyltransferase 2 (FUT2) enzyme and *α*1-2-fucosylated HMOs are absent in nonsecretors \[[@B3]\]. The LIFE cohort study of German mothers demonstrated that 2\'FL together with LNFP I and II are reliable proxies to define FUT 2 and 3 status, respectively. The changes in maternal FUT polymorphisms were the determinants of HMO variation with time \[[@B8]\].

3.2. Duration of Lactation {#sec3.2}
--------------------------

The HMOs vary in structure and composition over the course of lactation. A cross-sectional study of Chinese mothers reported that they produced unique types of HMOs during the different stages of lactation, independent of the mode of delivery and geographical location \[[@B9]\]. The overall HMO concentration decreases across lactation, but the direction of the change varies among specific HMOs. A study of HMOs in milk samples of German women from days 3 to 90 postpartum indicated that the levels of 2\'FL and LNFP I reduced with increasing duration of lactation, whereas levels of 3-fucosyllactose (3FL) increased in Se+ and Le+ women \[[@B10]\]. Therefore, the activity of Se- and Le-independent fucosyltransferases (FUT3, 4, 5, 6, 7, or 9) may increase across lactation \[[@B11]\]. However, the major small neutral HMOs and their isomers varied the least across lactation \[[@B12]\].

3.3. Gestation Period {#sec3.3}
---------------------

The total HMO concentration in milk of women who deliver preterm is greater than of those who deliver at term \[[@B13]\]. A mass spectrometric analysis of the fucosylation and sialylation in HMOs in serial milk specimens of women delivering preterm and term indicated that lacto-N-tetraose (LNT) was more abundant and more variable in preterm milk than in term milk. Moreover, the concentration of 2′-FL was not consistent across lactation for mothers with preterm delivery \[[@B14]\]. Thus, the fucosylation of HMOs in preterm milk may be unpredictable \[[@B11]\].

3.4. Maternal Health {#sec3.4}
--------------------

HMO concentrations were significantly lower in women with a body mass index (BMI) of 14 to 18 than in women with a BMI of 24 to 28 \[[@B3]\]. The ATLAS cohort study of European mothers indicated that the prepregnancy BMI and gestational weight gain may influence individual HMO levels. However, the effects of these on the HMO concentrations were small \[[@B15]\]. Gestational diabetes mellitus did not impact the level and composition of total HMOs \[[@B16]\].

4. Function of HMOs {#sec4}
===================

The multifarious functions of HMOs are as follows: (i) they act as prebiotics and stimulate the colonization of beneficial microbes, (ii) they exert direct defence mechanisms against pathogens and protect infants from infections, (iii) they act as signalling molecules and interact directly with the host cells, (iv) they act as anti-inflammatory and immune-modulators, and (v) they act as nutrients for neurological development of infants ([Figure 2](#fig2){ref-type="fig"}) \[[@B5]\].

4.1. Role of HMOs as Prebiotics {#sec4.1}
-------------------------------

The complex oligosaccharide mixture within HMOs attracts both mutualistic mucus adapted species and HMO-adapted bifidobacteria to the infant intestine \[[@B17]\]. Several in vitro studies have reported that bifidobacterial species can grow on HMOs \[[@B5]\]. This type of commensal feeding is one of the key factors influencing gut microbiota composition and development of immunity in infants \[[@B18]\]. Most of the HMOs are unabsorbed into the gut, where certain bacteria ferment them into short chain fatty acids creating an acidic environment. The low pH environment in the gut favours the growth of other strains of beneficial bifidobacteria \[[@B19]\]. HMOs do not allow the growth of potentially harmful bacteria by favouring the growth of*Bifidobacterium* species ([Figure 3](#fig3){ref-type="fig"}) \[[@B2]\]. Evidence suggests that breast-fed infants have a higher abundance of beneficial bifidobacteria compared with formula-fed infants \[[@B18]\].

The genomic study of*Bifidobacterium longum* subsp.*infantis* indicated that it is adapted for utilisation of the HMOs in the infant gut. The conservation of gene clusters in multiple isolates confirms the genomic mechanisms for this infant associated phylotype \[[@B20]\].*B. longum*subsp*. infantis* equally incorporates type 1 and type 2 HMOs, while other bifidobacterial species have preferential use for type 1 HMOs. The predominance of type 1 structures found in HMOs and the conservation of galacto-N-biose (GNB)/lacto-N-biose (LNB) pathway in bifidobacteria indicate that they have coevolved with humans \[[@B21]\]. Mass spectrometry-based glycoprofiling of the HMO consumption behavior revealed a specific preference for fucosylated oligosaccharides by*B. longum* subsp.*infantis* and*Bacteroides vulgatus* \[[@B22]\]. Small-mass HMOs, mainly secreted in the colostrum and during the first month of lactation, are preferred by*B. longum biovar infantis* ATCC 15697, which possesses fucosidase and sialidase activities \[[@B23]\]. A randomized controlled trial of healthy term infants indicated that formulae supplemented with two HMOs, 2\'FL and LNnT, may shift the gut microbiota composition towards that of breast-fed infants \[[@B24], [@B25]\]. Infants fed by nonsecretor mothers are late in the establishment of a bifidobacteria-laden gut ecosystem \[[@B26]\]. Child and mothers\' secretor status have an impact on children\'s microbiota composition at 2 to 3 years of age \[[@B27]\].

4.2. Antiadhesive Antimicrobial Properties of HMOs {#sec4.2}
--------------------------------------------------

HMOs are the major constituent of an innate immune system whereby the human milk protects the infant from enteric and other pathogens \[[@B28]--[@B30]\]. HMOs prevent the attachment of pathogens by serving as soluble glycan receptor decoys ([Figure 4](#fig4){ref-type="fig"}). HMOs directly reduce microbial infections by acting as antiadhesive antimicrobials and indirectly keep the pathogens in check by providing competitive advantage to nonpathogenic commensals \[[@B2]\]. HMOs may mimic structures of viral receptors and block adherence to target cells, thus preventing infection \[[@B31]\].

The sialylated fraction of HMOs showed a strong inhibitory capacity for hemagglutination mediated by enterotoxigenic*Escherichia coli* (ETEC) and uropathogenic*Escherichia coli* (UPEC) \[[@B32]\]. HMOs show a high efficiency in blocking the lectins that contribute to virulence of*Pseudomonas aeruginosa* \[[@B33]\]. Inhibition of the attachment of*Streptococcus pneumoniae* and*Haemophilus influenzae* to human pharyngeal or buccal epithelial cells is attributed to HMO fraction of the breast milk \[[@B34]\]. Jantscher-Krenn et al. demonstrated through*in vitro* studies that HMOs reduced the attachment and cytotoxicity of*Entamoeba histolytica* to intestinal epithelial cells \[[@B35]\]. Specific HMOs inhibit the binding of*Campylobacter jejuni* to the intestinal H-2 antigens \[[@B36]\]. The sialyl Lewis X and B receptors on porcine milk proteins prevent the colonisation of*Helicobacter pylori*\[[@B37]\]. The physiological concentrations of HMOs significantly reduce the gp120 binding of Human Immunodeficiency Virus (HIV)-1 virus to the dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN) on human dendritic cells by more than 80% \[[@B38]\]. DC-SIGN is selective in its recognition of specific types of fucosylated glycans and subsets of oligomannose- and complex-type N-glycans among HMOs \[[@B39]\]. Lewis X motif present in human milk can bind to DC-SIGN and thereby prevent the capture and subsequent transfer of HIV-1 to CD4+ T lymphocytes \[[@B40]\].

4.3. Effect of HMOs on Intestinal Epithelial Cells {#sec4.3}
--------------------------------------------------

The interaction of HMOs with pathogenic microbes prevents their attachment to the intestinal epithelial cells \[[@B7]\]. HMOs act directly on the intestinal epithelial cells and modulate their gene expression leading to changes in cell surface glycans and other responses ([Figure 5](#fig5){ref-type="fig"}). A study demonstrated that HMOs reduce cell growth and initiate differentiation and apoptosis in cultured human intestinal epithelial cells \[[@B2]\].

HMOs, especially disialyllacto-N-tetraose, contribute to protection from necrotising enterocolitis \[[@B41]\]. HMOs are effective at influencing various stages of intestinal epithelial cells during the gastrointestinal development in vitro \[[@B42]\]. HMOs inhibited intestinal cell proliferation and altered cell cycle dynamics by affecting corresponding regulator genes and mitogen-activated protein kinase signaling \[[@B43]\]. Acidic HMOs serve contribute to the lower incidence of inflammatory diseases such as necrotizing enterocolitis in breast-fed infants \[[@B44]\].

4.4. Impact of HMOs on Immune Cells {#sec4.4}
-----------------------------------

HMOs exert anti-inflammatory effect by reducing the platelet-neutrophil complex formation that contributes to a reduction in the neutrophil beta-2 integrin expression \[[@B44]\]. Specific HMOs serve as anti-inflammatory components by inhibiting the leukocyte rolling and adhesion to endothelial cells under dynamic conditions \[[@B45]\]. Acidic HMOs affect cytokine production and activation of cord blood derived T cells in vitro \[[@B46]\]. HMOs help in developing the immune system, potentially leading to a more balanced Th1/Th2 response ([Figure 6](#fig6){ref-type="fig"}).

Acidic HMOs may modulate postnatal allergen-specific immune responses by suppression of Th-2 type responses in atopy-prone individuals \[[@B47]\]. A randomized controlled trial reported that the healthy term infants fed formulas supplemented with 2\'-FL reduced the cytokine levels similar to those of a breast-fed reference group \[[@B48]\]. Infants born by C-section and having a high hereditary risk for allergies might have a lower risk to manifest IgE-associated eczema at 2 years when fed breast milk with FUT2-dependent HMOs \[[@B49]\].

4.5. Growth and Survival by HMOs {#sec4.5}
--------------------------------

A randomized controlled study of healthy term infants reported that the formulas supplemented with 2\'-FL were well tolerated, and 2\'-FL absorption profiles were similar to those of breast-fed infants. There were no significant differences in weight, length, and head circumference between infants fed human milk or 64.3 kcal/dL formulas from birth to 4 months of age \[[@B50]\]. Another randomized controlled trial of healthy infants indicated that the formula with 2\'FL and LNnT is safe, well-tolerated and supports age appropriate growth \[[@B51]\]. A cohort study of healthy mothers and infant pairs reported that the relatively substantial variation in HMOs between the high and low 2\'FL clusters do not impact infant growth of either sex up to 4 months of age \[[@B52]\]. A study of Gambian mothers and infants indicated that the HMO, 3′-sialyllactose, was a good indicator of infant weight-for-age \[[@B53]\]. A study of Zambian HIV+ mothers and infants demonstrated that breastfeeding was protective against mortality only in HIV exposed, uninfected children with high concentrations of fucosylated HMOs \[[@B54]\].

5. The Journey Ahead {#sec5}
====================

HMOs represent the next frontier in neonatal nutrition as they constitute a major component of the immune-protection conferred by breast milk upon vulnerable infants. Progress in clinical research has deemed supplementary provision of HMOs an attractive alternative for newborns who cannot be breast-fed. Although there have been significant breakthroughs in our knowledge about the HMOs, there are many key questions that need to be answered. Basic science should dictate the specific choice of HMOs and clinical data should justify the need for supplementing the infant formulas with them. Clinical research could be directed towards addressing pertinent queries such as which are the specific HMOs, in what quantity and for how long should they be administered. Basic research has hitherto laid a firm groundwork for clinical research on HMOs, which in turn has engendered new questions about their clinical implications.

"*Science never solves a problem without creating ten more.*"*George Bernard Shaw*
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![Structural blueprint of HMOs. The glucose, galactose,*N*-acetylglucosamine, fucose, and N-acetylneuraminic acid molecules are the building blocks for HMOs.](IJPEDI2019-2390240.001){#fig1}

![Potential benefits for breast-fed neonates. HMOs may serve as prebiotics, immune-modulators, and signalling molecules to enhance the gut immunity of newborns.](IJPEDI2019-2390240.002){#fig2}

![Type of gut microbiota in (a) absence of HMOs and (b) presence of HMOs. The growth of beneficial bifidobacteria is favoured by HMOs over that of pathogens in the gut.](IJPEDI2019-2390240.003){#fig3}

![Adhesion of pathogens to gut wall in (a) absence of HMOs and (b) presence of HMOs. The adhesion of the pathogens to the gut wall is prevented by HMOs that serve as decoy.](IJPEDI2019-2390240.004){#fig4}

![Gut epithelial cells in (a) absence of HMOs and (b) presence of HMOs. The interaction with HMOs leads to altered gene expression and growth of the intestinal epithelial cells.](IJPEDI2019-2390240.005){#fig5}

![T-cell response in (a) absence of HMOs and (b) presence of HMOs. The modulation of the immune system by the HMOs leads to a more balanced T-cell response.](IJPEDI2019-2390240.006){#fig6}
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